Close
Resource Documents
Online Inquiry

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Immune Cell-based Therapies

The immune system has the functions of immune surveillance, defense and regulation. This system consists of immune organs (bone marrow, spleen, lymph nodes, etc.), immune cells (lymphocytes, phagocytes, mast cells, etc.), as well as immunoreactive substances (antibodies, lysozyme, complements, cytokines, etc.). The immune system is divided into innate immunity (also known as non-specific immunity) and adaptive immunity (also known as specific immunity), and adaptive immunity is divided into humoral immunity and cellular immunity. Creative Biolabs concludes the main types of immune cells and their respective functional roles in the immune system. Therapeutics based on these immune cells are also summarized.

B Cell-based Immunotherapy
Dendritic Cell-based Immunotherapy
Macrophage-based Immunotherapy
Neutrophil-based Immunotherapy
Mast Cell-based Immunotherapy

Contents

  • Types, Locations and Functions of Immune cells
    • T Cells
    • Dendritic Cells
    • B Cells
    • Neutrophils
    • NK Cells
    • Mast Cells
    • Macrophages
  • Immune Cell-based Therapies
    • Small Molecules Targeting Immune Checkpoints
    • Monoclonal Antibodies Targeting Immune Cells
    • Adoptive Transfer of Genetically Engineered Immune Cells
    • Immune Cell Vaccine

Types, Locations and Functions of Immune Cells

Immune cells are commonly known as white blood cells, including lymphocytes and various phagocytes, but they can also refer to lymphocytes that can recognize antigens and produce specific immune responses. Lymphocytes are the basic components of the immune system, widely distributed in the body, mainly T lymphocytes and B lymphocytes, which are stimulated by antigen and activated to divide, proliferate and produce specific immune response. In addition to T and B lymphocytes, there are K lymphocytes and NK (natural killer) lymphocytes, a total of four lymphocyte types,among which T lymphocytes are a multifunctional group of cells. In addition to lymphocytes, the cells involved in the immune response are plasma cells, granulocytes, mast cells, antigen presenting cells and mononuclear phagocytic cells. Table 1 lists major types, locations and functions of immune cells. More detailed introductions of certain types of immune cells with significant roles are described following the table.

Table 1. Major types, locations and functions of immune cells

Cell Type Location and Function
Leukocytes Derived from myeloid or lymphoid lineage, these are the main cells in immune system, which provide either innate or specific adaptive immunity. Myeloid cells include phagocytic, motile neutrophils, monocytes, and macrophages, providing the first-line defense against pathogens. Other myeloid cells involved in defense against parasites & in genesis of allergic reactions include eosinophils, basophils & mast cells. Lymphocytes regulate the action of other leukocytes & generate specific responses to prevent chronic/recurrent infections.
B cells In mammals, B cells mature in the bone marrow, while in birds, B cells mature in the bursa of Fabricius, a lymphoid organ first discovered by Chang and Glick. They develop into antibody-secreting plasma cells. B cells express B cell receptors (BCRs) on their cell membrane that allows them to bind to specific antigen, against which it initiates a specific antibody response.
T cells Originate in the bone marrow and mature in the thymus giving rise to helper, regulatory, cytotoxic T cells, or memory T cells. From the thymus, they migrate to peripheral tissues, blood, & lymphatic system. On stimulation, they secrete chemical messengers called cytokines, which stimulate the differentiation of B cells into antibody-producing cells also called plasma cells. Cytotoxic T cells in the presence of various cytokines bind to and kill infected cancer cells.
T helper cells Subset of T cells, found throughout the body, with especially high titers in lymphoid organs (lymph nodes and spleen), as well as the liver, lung, blood, and the intestinal tract. T helper TH or CD4+ T cells coordinate and regulate immunological responses. TH cells mediate responses by secreting lymphokines that act on other cell types involved in mounting an immune response.
T cytotoxic cells Subset of T cells, found throughout the body, with especially high titers in lymphoid organs (lymph nodes & spleen), as well as the liver, lung, blood, and the intestinal tract. T cytotoxic Tc or CD8+ T cells are involved in directly killing virus-infected cells, transplanted cells, and sometimes, eukaryotic parasites and tumor cells. CD8+ T cells have been shown to play a role in downregulating the immune response.
Natural Killer cells Similar to Tc cells, NK cells directly kill certain tumors such as melanomas, lymphomas and virus-infected cells and clear herpes and cytomegalovirus-infected cells. In contrast to Tc cells, NK cells kill their target cells more effectively without the need for recognition of antigen in association with MHC molecules and are activated by secretions from TH cells.
Macrophages These are phagocytic cells and function as antigen-presenting cells (APCs) as they ingest foreign materials and present these to other members of the immune system such as T cells and B cells. Besides being the initiators of an immune response, they also act as immune modulators by secreting cytokines and can also be stimulated by lymphokines, to exhibit increased levels of phagocytosis.
Dendritic cells Originate in the bone marrow and form another class of APCs. These are found in the lymphoid organs such as the thymus, lymph nodes, and spleen along with the bloodstream and other tissues. They function to capture and process antigens in lymphoid organs at the time of initiation of an immune response.
Neutrophils These cells, which ingest, kill, and digest pathogens, are the most highly adherent and motile phagocytic leukocytes, and the first cell types to be recruited to acute inflammatory sites. Their functions are dependent on adherence molecule CD11b/CD18, or biochemical pathways, such as the respiratory burst associated with cytochrome b558.
Eosinophils Defend against parasites and participate in hypersensitivity reactions. Their cytotoxicity is mediated through cytoplasmic granules containing eosinophilic basic and cationic proteins.
Basophils Along with their tissue counterparts, mast cells produce cytokines required for defense against parasites and allergic inflammation. They display surface membrane receptors for IgE antibodies and possess cytoplasmic granules containing heparin and histamine. When cell-bound IgE antibodies are cross linked by antigens, the eosinophils degranulate releasing low-molecular weight vasoactive mediators (e.g., histamine), which mediate their biological effects.
Monocytes/macrophages These are involved in phagocytosis and intracellular killing of microorganisms. Macrophages are differentiated monocytes, residing in the reticuloendothelial systems and act as antigen-presenting cells presenting processed peptides to T cells. They are recruited to inflammatory sites and further activated by exposure to certain cytokines, which potentiate their biologic functions.

T Cells

Immune Cell-based TherapiesT cells are also known as thymus dependent lymphocytes, which come from pluripotent stem cells from bone marrow (in embryonic stage come from yolk sac and liver). The pluripotent stem cells migrate into the thymus and differentiates into immune T cells induced by thymic hormones. T cells are a kind of cells with the largest number and the most complex function in lymphocytes. According to its function, it can be divided into three main subgroups: helper T cells, inhibitory T cells and cytotoxic T cells. T cells are the main components of lymphocytes, which have a variety of biological functions, such as directly killing target cells, assisting or inhibiting B cells to produce antibodies, responding to specific antigens and mitogen, and producing cytokines, which are significant for the body to resist disease infection, tumor formation of heroic fighters. The immune response produced by T cells is cellular immunity. There are two main forms of cellular immunity: one is specific binding to target cells, destruction of target cell membrane and direct killing of target cells; the other is the release of lymphoid factor, which ultimately expands and enhances the immune effect.

B Cells

Immune Cell-based TherapiesB lymphocytes are also referred to as B cells, which are derived from pluripotent stem cells of bone marrow. Compared with T cells, B cells are slightly larger. Mature B cells migrate out of peripheral blood and enter spleen and lymph nodes, which are mainly distributed in splenic nodules, splenic cord, lymphoid nodules, lymphatic cords and submucosal lymphoid nodules of digestive tract. Stimulated by antigen, they differentiate and proliferate into a large number of plasma cells, synthesize and secrete antibodies and circulate in the blood, thus give full play to the function of humoral immunity. Most vaccines used today produce antibodies by stimulating these B lymphocytes. The number of B cells in bone marrow and collecting lymph nodes is higher than that in blood and lymph nodes, and even less in thoracic ducts. Only a few of them participate in recirculation. There are many different markers on the cell membrane of B cells, mainly surface antigens and surface receptors. These surface markers are giant protein molecules that bind to the cell membrane. B1 cells are T cell-independent cells, while B2 is T cell-dependent. B cells survive for a short period of time in the body, only a few days to a few weeks, but their memory cells can exist for a long time.

NK Cells

Immune Cell-based TherapiesNatural killer (NK) cells are derived from bone marrow lymphoid stem cells. Their differentiation and development depend on bone marrow and thymus microenvironment. They are mainly distributed in bone marrow, peripheral blood, liver, spleen, lung and lymph nodes. Different from T and B cells, NK cells are a kind of lymphocytes which can kill tumor cells and virus infected cells without pre-sensitization. The killing activity of NK cells is not limited by major histocompatibility complex (MHC) and does not depend on antibodies, thus it is called natural killing activity. NK cells are rich in cytoplasm and contain large azurophilic granules. The content of granules is positively correlated with the killing activity of NK cells. The target cells of NK cells are mainly some tumor cells (including some cell lines), virus infected cells, some self-tissue cells (such as blood cells), parasites and so on. Therefore, NK cells are important immune factors for anti-tumor and anti-infection. It is also involved in type II hypersensitivity and graft-versus-host response. The main killing mediators of NK cells are perforin, NK cytotoxic factors and tumor necrosis factors (TNFs).

Macrophages

Immune Cell-based TherapiesMacrophage (Mø) is a kind of white blood cell in tissue, which comes from monocytes, which in turn come from progenitor cells in bone marrow. Macrophages and monocytes are phagocytes and are involved in non-specific defense (innate immunity) and specific defense (cellular immunity) in vertebrates. Their main function is to phage cell fragments and pathogens (that is, phagocytosis and digestion) in the form of fixed cells or free cells, and activate lymphocytes or other immune cells to respond to pathogens. Macrophages are amoeba-like cells that devour and treat large foreign bodies, old waste excreted by cells, red blood cells at the end of their lives, and go to the site of inflammation to deal with foreign bodies. Macrophages are a kind of white blood cells with a wide range of protection, which exist not only in the blood, but also in the whole body. Depending on the location, the name and shape vary. Monocytes circulate to the whole body with the blood and run to the inflammatory site. The defense system of the single-celled biological age is quite simple, with macrophages phagocytosis of foreign bodies, making it become garbage and excrete out of the body.

Dendritic Cells

Immune Cell-based TherapiesDendritic cells (DCs), discovered by Canadian scholar Steinman in 1973, are the most powerful antigen-presenting cells (APCs), named after many dendritic or pseudopod processes when they mature. Dendritic cells have no specific cell surface molecular markers, which are mainly identified by morphology, combinatorial cell surface markers, activation of initial T cells in mixed lymphocyte reaction and so on. DCs are originated from bone marrow pluripotent hematopoietic stem cells. There are two main ways of DC differentiation: (1) myeloid stem cells differentiate into DC, under the stimulation of GM-CSF, which is called myeloid DC (MDC), also known as DC1; (2) derived from lymphoid stem cells, called lymphoid DC (LDC) or plasma cell-like DC (pDC), also known as DC2. DCs are widely distributed in the skin, airway, lymphoid organs and other parts, with a high degree of heterogeneity. Most of DCs in human body are in immature state, expressing low levels of costimulatory factors and adhesion factors, and the ability to stimulate the proliferation of allogeneic mixed lymphocytes is low, but immature DCs have strong antigen phagocytosis. When ingested antigens or stimulated by some factors, the immature DCs differentiated into mature DCs which expressed high levels of costimulatory factors and adhesion factors. As the most powerful APCs, they can induce specific cytotoxic T lymphocyte (CTL) production.

Mast Cells

Immune Cell-based TherapiesMast cells come from hematopoietic stem cells, but in fact, mast cells that have just entered the peripheral circulatory system from the bone marrow are still immature, only when their precursor cells migrate to the place where they eventually settle. That is, differentiation and/or maturation can only be completed in vascular tissue or serous cavity. Mast cells are widely distributed around the microvessels under the skin and visceral mucosa, which are often exposed to pathogens, allergens and other environmental substances. Mast cells secrete a variety of cytokines, express MHC and B7 molecules and IgE Fc receptors, and release allergic mediators. They also behave weak phagocytosis. The distribution and function characteristics of mast cells make them together with dendritic cells become the first cell groups in the hematopoietic-immune system to interact with allergens, other antigens and invasive pathogens in the hematopoietic-immune system.

Neutrophils

Immune Cell-based TherapiesNeutrophils are colorless or light red cytoplasm in Wright's stained blood smears. Neutrophils, which come from bone marrow and have lobulated or rod-shaped nuclei, have chemotaxis, phagocytosis and bactericidal effect. The cytoplasm contains a large number of neutral fine particles that are neither basophilic nor eosinophilic. Most of these particles are lysosomes, which contain rich enzymes such as myeloperoxidase, lysozyme, alkaline phosphatase and acid hydrolase, and they are related to the phagocytosis and digestion of cells.

Immune Cell-based Therapies

Based on the significant roles of T cells in the immune system, many small-molecule drugs targeting T cells and T-cell based immunotherapies have been developed for the treatment of intractable diseases including autoimmune diseases and cancer. T-cell based immunotherapies mainly utilize the mechanisms of T cell-mediated immune responses and the effects of some other immune cells such as DCs, natural killer (NK) cells, and macrophages. Currently developed T cell-based immunotherapies mainly include monoclonal antibodies targeting T cells, adoptive transfer of genetically engineered T cells, and T cell vaccine.

Small Molecules Targeting Immune Checkpoints

Immune Cell-based Therapies Both health cells (including immune cells, especially T cells) and tumor cells express multiple receptor and/or ligand molecules on their membrane and into the tumor microenvironment. Several of these molecules participate in pairs in stimulating or inhibiting immune progress, which are known as immune checkpoints. When immune system is attacking pathogens, these immune checkpoint molecules can protect the normal tissues from damage. The cancer cells cleverly escape from immune attack by dysregulating immune checkpoint related proteins. This has led to the development of several checkpoint-targeted small-molecule and monoclonal antibody drugs that are currently being tested in clinical trials or have been approved for a number of cancers. Small molecule drugs have desirable benefits over monoclonal antibodies, including greater cell permeability, organ specificity, longer half-lives, cheaper production costs, and the possibility for oral administration. Currently developing small molecule inhibitors targeting immune checkpoints and the related cellular pathways are listed in Table 2.

Table 2. Current small molecule inhibitors targeting immune checkpoints and cellular pathways

Immune Checkpoint Small Molecule Inhibitors Cell Pathways
PD-1/PD-L1 BMS-8, 37, 202, 230, 242, 1001, 1166, SB415286*, vorinostat*, panobinostat*, azacitidine*, decitabine*, entitostat*, JQ1*, I-BET151*, GSK503* Invasion, Angiogenesis, T-Cell suppression,
CTLA4 Compounds “8 and 9”, entitostat*, panobinostat*, ACY-241*, azacytidine* Angiogenesis, T-Cell activation, Cell signaling
OX40 DB36, DB71, DB15, CVN, MGCD0103*, SNDX-275*, azacytidine* Angiogenesis, Cell activation, Tumor necrosis
LAG-3 IMP32, BMS986016 T-Cell proliferation, Cell maturation & activation
TIM-3 TSR-022, Sym023, ATIK2a Tumorigenesis, Cell invasion & activation
B7-H3 c-MYC SMIs, vorinostat*, DZNep* Migration, Angiogenesis, Cellular cycle & signaling

*, Epigenetic SMI.

Monoclonal Antibodies Targeting Immune Cells

Immune Cell-based Therapies Monoclonal antibody (mAb)-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors in the last decades. The main desired mechanism of action is engagement with cell surface receptors (to either activate or inhibit signaling), or to activate/mediate antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cell-mediated cytotoxicity (CDCC), and programmed cell death (PCD). Most of the monoclonal antibodies are designed to target various antigens existing in the tumor microenvironment, including tumor antigens, cytokines, immune checkpoints, and marker molecules expressed on the membrane of immune cells. As a group of immune cell surface glycoproteins with a multitude of functions, the clusters of differentiation (CD antigens) provide the interface between a cell and the external environment that includes other cells. Serving as receptors and ligands, CD antigens regulate cell signaling and immune response, making them popular in therapeutic antibody development. Table 3 lists some therapeutic antibodies (including some antibody-drug conjugates) that target CD antigens on immune cells.

Table 3 . Therapeutic antibodies targeting CD antigens on immune cells

CD Antigen Cell Therapeutic Antibody Indication(s)
CD147 Leukocyte Ziralimumab Cancers, NSCLC, solid tumors, bladder, urothelial
Gavilimomab Cancers, ovarian, gastric, NSCLC, metastatic, solid tumors
CD192 Macrophage Plozalizumab Solid tumors
CD194 T Cell Mogamulizumab Solid tumors
CD15 Monocyte, Neutrophil, Promyelocyte Fanolesomab Inflammatory diseases
CD19 B cell, DC Inebilizumab AML
Coltuximab Ravtansine AML
Denintuzumab Mafodotin ALL, B-cell NHL
Blinatumomab NHL
Taplitumomab Paptox CLL
CD2 T Cell, NK Cell Siplizumab MM
CD200 B cell, T Cell, DC Samalizumab Multiple myeloma
CD22 B Cell Epratuzumab Type 1 diabetes
Inotuzumab Ozogamicin Psoriasis
Moxetumomab Pasudotox Atherosclerosis
Pinatuzumab Vedotin Prostate cancer
Bectumomab NHL
CD248 T Cell Ontuxizumab Breast cancer
CD27 B cell, T Cell, NK Cell Varlilumab Kidney transplantation
CD274 B cell, T Cell, Monocyte, Macrophage, DC Atezolizumab HIV-1 infection, AIDS
Durvalumab Psoriasis
Avelumab Cutaneous T cell lymphoma (CTCL)
CD276 DC, B Cell, Macrophage Enoblituzumab RA
CD28 T Cell Lumretuzumab Asthma
Lulizumab Pegol Allograft rejection
CD33 T Cell, NK Cell Lintuzumab CD
Vadastuximab MM
Gemtuzumab Ozogamicin Lymphoma, B cell
CD37 B Cell, T Cell, Monocyte Lilotomab Solid tumors
Otlertuzumab CLL
CD38 B cell, T Cell, NK Cell Daratumumab MM, DLBCL, follicular lymphoma, mantle cell lymphoma
Isatuximab Squamous cancer
CD3D T Cell Teplizumab T1DM
CD3E T Cell Otelixizumab GvHD
Foralumab CLL
Pasotuxizumab MS
Catumaxomab Veterinary antineoplastic
Ertumaxomab Psoriasis
Visilizumab NHL
CD4 T Cell, Monocyte, Macrophage, DC Ibalizumab Autoimmune diseases
Tregalizumab MM
Zanolimumab CLL
Keliximab NHL
Clenoliximab Colorectal cancer
Cedelizumab Colorectal cancer
Priliximab Colorectal cancer
CD40 B Cell, Macrophage, DC Dacetuzumab Osteomyelitis
Bleselumab Bone marrow scintigraphy
Selicrelumab Solid tumors
Lucatumumab RA, PVNS
Teneliximab RA
CD44 Leucocytes Bivatuzumab Head and neck cancer
Bivatuzumab Mertansine Melanoma, metastatic
CD5 B cell, T Cell Zolimomab Aritox Solid tumors
Telimomab Aritox Prostate cancer
CD52 B cell, T Cell, Monocyte, Macrophage Alemtuzumab Breast cancer
Tamtuvetmab Breast cancer
CD6 T Cell Itolizumab Cancers
CD70 B cell, T Cell, DC Vorsetuzumab Mafodotin Malignant melanoma
Vorsetuzumab Renal transplant rejection
CD74 B cell, Monocyte, Macrophage, DC Milatuzumab SLE
CD79B B cell Polatuzumab Vedotin NSCLC
CD80 B cell, T Cell, DC Galiximab Solid tumors
CD66A Neutrophil Arcitumomab NSCLC
CD66E Neutrophil Labetuzumab Blood cancer
Altumomab Psoriasis
CD66C Neutrophil Sulesomab PSA
Lemalesomab Cancers
CD66B Neutrophil Besilesomab GvHD
CD115 Macrophage, DC, Neutrophil Emactuzumab Kidney transplant rejection, acute
Cabiralizumab MS
CD116 Monocyte Mavrilimumab Asthma, AD, Nasal polyposis, Esophagitis eosinophilic
CD152 T Cell Ticilimumab Asthma
Ipilimumab NMO
CD60A T Cell Ecromeximab Allograft rejection
CD54 B Cell Enlimomab Pegol Psoriasis
CD275 B cell, Monocyte, Macrophage, DC Prezalumab Colorectal cancer, metastatic
CD217 granulocyte, Monocyte, Macrophage, DC, T cell, B cell, NK cell Ixekizumab NSCLC
Brodalumab Cancers
CD25 T cell, B Cell, Monocyte Inolimomab AML
Basiliximab Head and neck cancer
Daclizumab MS
CD124 B cell, T cell, Monocyte Dupilumab Allergic diseases
CD125 B cell, Mast cell Benralizumab NHL
CD126 B cell, Leucocyte Satralizumab WG, PA
Tocilizumab NHL
CD49B T cell, NK cell Vatelizumab NHL
CD49D Monocyte, NK cell, B Cell, T cell Etrolizumab Canine B-cell lymphoma
CD49E T cell, B cell Volociximab NHL
CD11A Leukocyte Odulimomab Prevention of transplant rejection
Efalizumab RA
CD51 T Cell, Granulocyte Abituzumab DLBCL
Intetumumab Solid tumors
CD18 Neutrophil, Monocyte, NK cell, T Cell Rovelizumab Solid tumors
Erlizumab Heart attack, stroke, and traumatic shock
CD158A, CD158B1, CD158B2 NK cell, T cell Lirilumab Gastric cancer
CD159A B cell, T cell Monalizumab Breast cancer
CD20 NK cell, T cell Ocrelizumab Epithelial Ovarian cancer
Ublituximab Solid tumors
Veltuzumab Inflammatory lesions
Rituximab SCLC
Ibritumomab Tiuxetan Solid tumors
Ocaratuzumab Solid Tumours, Pancreatic and Colorectal cancer
Epitumomab Hodgkin lymphoma
Blontuvetmab Canine B-cell lymphoma
Tositumomab Breast Cancer, Lung Cancer
Ibritumomab Cancers
Ofatumumab Cancers
Obinutuzumab Ovarian cancer
Afutuzumab GBM
CD227 T cell, B cell, Monocyte, DC Pemtumomab Cancers, ovarian, peritoneal
Clivatuzumab Tetraxetan Pancreatic cancer
Cantuzumab Mertansine Haemolytic disease of newborn
Nacolomab Tafenatox MM
Cantuzumab Ravtansine SCD
Sontuzumab Myocardial infection
Epitumomab Cituxetan MM
Gatipotuzumab Colorectal cancer
CD56 T cell, NK cell Lorvotuzumab Mertansine Colorectal cancer
CD304 T cell, DC Vesencumab Solid malignancies
CD73 B Cell, T cell Oleclumab NSCLC
CD279 B Cell, T cell, DC Pidilizumab Solid tumours
Pembrolizumab Advanced Solid Tumors
Camrelizumab HL
Nivolumab HL
Gilvetmab Tumors
CD138 B cell Indatuximab Ravtansine MM
CD319 Monocyte, Macrophage, DC, T cell, B cell, NK cell Elotuzumab MM
CD261 Leucocyte Mapatumumab Cancers
CD262 T cell, NK cell Lexatumumab Cancers
Drozitumab Chondrosarcoma, colorectal cancer, NHL, NSCLC
Tigatuzumab Cancers, pancreatic, colorectal, non-small cell lung, ovarian
Conatumumab Sarcoma, lymphoma, colon cancer, rectal cancer
CD134 T cell Vonlerolizumab Solid tumours
Tavolixizumab Solid tumours
CD30 B Cell, T cell Iratumumab Relapsed refractory CD30-positive lymphoma
Brentuximab Vedotin HL, ALCL
CD137 T cell, B cell, Monocyte, DC Urelumab Cancers, solid tumors
Utomilumab Cancers
CD254 T cell Denosumab Osteoporosis
CD257 B Cell Tabalumab Autoimmune diseases, B cell malignancies
Belimumab SLE
CD252 T cell Oxelumab Asthma
CD51/CD61 Monocyte, Macrophage Etaracizumab Metastatic melanoma, prostate cancer, ovarian cancer

DC, dendritic cell. NK, natural killer. NSCLC, non-small cell lung. SLE, systemic lupus erythematosus. HL, Hodgkin lymphoma. ALCL, anaplastic large cell lymphoma. NHL, non-Hodgkin lymphoma. MM, multiple myeloma. SCD, sickle cell disease. GBM, glioblastoma multiforme. SCLC, small cell lung cancer. DLBCL, diffuse large B cell lymphoma. RA, rheumatoid arthritis. WG, Wegener's granulomatosis. MPA, microscopic polygamiitis. MS, multiple sclerosis. AML, acute myeloid leukemia. NMO, neuromyelitis optica. GvHD, graft-versus-host disease. AD, atopic dermatitis. PSA, psoriatic arthritis. PVNS, pigmented villonodular synovitis. CLL, chronic lymphocytic leukemia. T1DM, type 1 diabetes mellitus. CD, Crohn's disease. ALL, acute lymphoblastic leukemia.

Adoptive Transfer of Genetically Engineered Immune Cells

Immune Cell-based Therapies Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT has multiple advantages compared with other forms of cancer immunotherapy that rely on the active in vivo development of sufficient numbers of antitumor T cells with the functions necessary to mediate cancer regression. For use in ACT, large numbers of immune cells including anti-tumor lymphocytes can be readily grown in vitro and selected for high-avidity recognition of the tumor, as well as for the effector functions required to mediate cancer regression. In vitro activation allows such cells to be released from the inhibitory factors that exist in vivo. Perhaps most importantly, ACT enables the manipulation of the host before cell transfer to provide a favorable microenvironment that better supports antitumor immunity. ACT is a “living” treatment because the administered cells can proliferate in vivo and maintain their antitumor effector functions.

ACT has used either natural host cells that exhibit antitumor reactivity or host cells that have been genetically engineered with anti-tumor T cell receptors (TCRs) or chimeric antigen receptors (CARs). With the use of these approaches, ACT has mediated dramatic regressions in a variety of cancer histologies, including melanoma, cervical cancer, lymphoma, leukemia, bile duct cancer, and neuroblastoma. For CAR-T cell therapy, while the mechanism of action is not fully understood, evidence suggests that CAR T cell therapies stimulate a T cell response against antigen-expressing cells, including normal and malignant cells. The external targeting domain binds to the antigen, activating the CAR-T cell. Once activated, CAR-T cells release cytokines and other soluble mediators that may directly kill antigen-expressing target cells and normal cells. Two autologous CAR-T cell therapies (Kymriah™ and Yescarta™) have been approved by the Food and Drug Administration (FDA) and the Europe Union. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta™ is for the treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T cell therapies lysing CD19-positive targets.

Current develop of cancer therapies that based on adoptive transfer of genetically engineered immune cells mainly focus on T cells, NK cells, macrophages, and dendritic cells. Currently developed and developing adoptive cell therapies based on CAR/TCR-modified immune cells mainly are CAR-T, TCR-T, CAR-NK, CAR-NKT, and CAR-Macrophage. Table 4 lists some of these adoptive cell therapies in clinical trials.

Table 4 . Clinical trials of adoptive cell therapies based on CAR/TCR-modified immune cells

Type Nct_id Title Condition Status Lead_sponsor Study_first_posted
CAR-T NCT03423992 Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Glioma, Malignant Glioma of Brain, Recurrence Tumor Recruiting Xuanwu Hospital, Beijing February 6, 2018
CAR-T NCT03758417 A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Multiple Myeloma Recruiting Nanjing Legend Biotech Co. November 29, 2018
CAR-T NCT03874897 Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. Advanced Solid Tumor Recruiting Peking University March 14, 2019
CAR-T NCT03938987 Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Not yet recruiting University of Alberta May 6, 2019
CAR-T NCT03241940 Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Recruiting Crystal Mackall, MD August 8, 2017
CAR-T NCT03884751 Chimeric Antigen Receptor T Cells Targeting Glypican-3 Hepatocellular Carcinoma Not yet recruiting Carsgen Therapeutics, Ltd. March 21, 2019
CAR-T NCT03434769 AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma Non-Hodgkin Lymphoma Recruiting Case Comprehensive Cancer Center February 15, 2018
CAR-T NCT02442297 T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors Brain Tumor, Recurrent, Brain Tumor, Refractory Recruiting Baylor College of Medicine May 13, 2015
CAR-T NCT03233854 Phase I CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies B Acute Lymphoblastic Leukemia, CD19 Positive, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Recruiting Crystal Mackall, MD July 31, 2017
CAR-T NCT03118180 CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma Lymphoma Recruiting Zhejiang University April 18, 2017
CAR-T NCT02992834 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Lymphoma, B Cell Not yet recruiting jiangjingting December 14, 2016
CAR-T NCT02349698 A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma Leukemia, Lymphoma Recruiting Southwest Hospital, China January 29, 2015
CAR-T NCT03579888 CD19+ Specific Chimeric Antigen Receptor T Cells in Treating Participants With CD19+ Lymphoid Malignancies Acute Lymphoblastic Leukemia, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, CD19 Positive, Chronic Lymphocytic Leukemia, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma Not yet recruiting M.D. Anderson Cancer Center July 9, 2018
CAR-T NCT03624686 Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies Leukemia Recruiting National Taiwan University Hospital August 10, 2018
CAR-T NCT02659943 T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies Lymphoma, B-Cell, Lymphoma, Non-hodgkins Active, not recruiting National Cancer Institute (NCI) January 21, 2016
CAR-T NCT03291444 CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), Myelodysplastic Syndromes Recruiting Zhujiang Hospital September 25, 2017
CAR-T NCT04082910 Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Solid Tumor, Hematologial Malignancy Recruiting Chinese PLA General Hospital September 10, 2019
CAR-T NCT04049513 ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) Not yet recruiting Malaghan Institute of Medical Research August 8, 2019
CAR-T NCT03086954 Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma Lymphoma Not yet recruiting Sinobioway Cell Therapy Co., Ltd. March 22, 2017
CAR-T NCT03890198 A Phase 1 Study of LCAR-C182A/LCAR-C182B/LCAR-C182C Cells,a Chimeric Antigen Receptor T-cell (CAR-T) Gastric Cancer, Pancreatic Ductal Adenocarcinoma Recruiting First Affiliated Hospital Xi'an Jiaotong University March 26, 2019
CAR-T NCT01822652 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Neuroblastoma Active, not recruiting Baylor College of Medicine April 2, 2013
CAR-T NCT04029038 Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma Not yet recruiting M.D. Anderson Cancer Center July 23, 2019
CAR-T NCT03980288 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 Advanced Hepatocellular Carcinoma Not yet recruiting Zhejiang University June 10, 2019
CAR-T NCT03327285 C-CAR011 Treatment in Subjects With ALL After HSCT Acute Lymphoblastic Leukemia(ALL) Not yet recruiting Peking University People's Hospital October 31, 2017
CAR-T NCT02813837 Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies Leukemia, B-Cell, Lymphoma, B-Cell Recruiting Innovative Cellular Therapeutics Co., Ltd. June 27, 2016
CAR-T NCT02259556 CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Recruiting Chinese PLA General Hospital October 8, 2014
CAR-T NCT03971799 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia Acute Myelogenous Leukemia Not yet recruiting Center for International Blood and Marrow Transplant Research June 3, 2019
CAR-T NCT01087294 Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell Recruiting National Cancer Institute (NCI) March 16, 2010
CAR-T NCT03076437 Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma Recruiting Shenzhen Institute for Innovation and Translational Medicine March 10, 2017
CAR-T NCT02905188 Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) Hepatocellular Carcinoma Recruiting Baylor College of Medicine September 19, 2016
CAR-T NCT02932956 Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) Liver Cancer Pediatric Recruiting Baylor College of Medicine October 13, 2016
CAR-T NCT02456350 Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Lymphoma Recruiting Shenzhen Second People's Hospital May 28, 2015
CAR-T NCT03049449 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Lymphoma, Large-Cell, Anaplasitc, Hodgkin Disease, Lymphoma, Hodgkins, Enteropathy-Associated T-Cell Lymphoma Active, not recruiting National Cancer Institute (NCI) February 10, 2017
CAR-T NCT04093648 T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) Hepatocellular Carcinoma, Hepatoblastoma Not yet recruiting Baylor College of Medicine September 18, 2019
CAR-T NCT03548207 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma Multiple Myeloma Recruiting Janssen Research & Development, LLC June 7, 2018
CAR-T NCT03302403 Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma, Pancreatic Carcinoma, Adenocarcinoma of Esophagogastric Junction Not yet recruiting Kang YU October 5, 2017
CAR-T NCT03696030 HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases HER2/Neu Positive, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges Recruiting City of Hope Medical Center October 4, 2018
CAR-T NCT00902044 Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Sarcoma Recruiting Baylor College of Medicine May 14, 2009
CAR-T NCT03500991 HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma Recruiting Seattle Children's Hospital April 17, 2018
CAR-T NCT03144583 Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy Leukemia, Lymphoma Active, not recruiting Sara V. Latorre May 9, 2017
CAR-T NCT03448978 Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma Multiple Myeloma Recruiting Cartesian Therapeutics February 28, 2018
CAR-T NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia Recruiting Fred Hutchinson Cancer Research Center September 11, 2017
CAR-T NCT04089215 CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Recruiting Shanghai Ming Ju Biotechnology Co., Ltd. September 13, 2019
CAR-T NCT03614858 CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. Leukemia, B-cell Recruiting Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd August 3, 2018
CAR-T NCT03999697 A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Primary Cutaneous Follicle Centre Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mantle Cell Lymphoma, Plasma Cell Neoplasm, B Cell Lymphoma Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. June 27, 2019
CAR-T NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma Not yet recruiting Jonsson Comprehensive Cancer Center July 3, 2019
CAR-T NCT04003649 IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma Recurrent Glioblastoma, Refractory Glioblastoma Not yet recruiting City of Hope Medical Center July 1, 2019
CAR-T NCT04008251 Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Acute Lymphoblastic Leukemia, B Cell Lymphoma Recruiting Wuhan Sian Medical Technology Co., Ltd July 4, 2019
CAR-T NCT02765243 Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma Neuroblastoma, Effects of Immunotherapy Recruiting Zhujiang Hospital May 6, 2016
CAR-T NCT02965092 CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Acute Lymphoblastic Leukemia, B Cell Lymphoma Recruiting Wuhan Sian Medical Technology Co., Ltd November 16, 2016
CAR-T NCT02349724 A Clinical Research of CAR T Cells Targeting CEA Positive Cancer Lung Cancer, Colorectal Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer Recruiting Southwest Hospital, China January 29, 2015
CAR-T NCT03851146 A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours Advanced Cancer Recruiting Peter MacCallum Cancer Centre, Australia February 22, 2019
CAR-T NCT03448393 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, Lymphoma, Non-Hodgkin Recruiting National Cancer Institute (NCI) February 28, 2018
CAR-T NCT03954106 A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity DLBCL, Neurotoxicity Syndromes Not yet recruiting Jazz Pharmaceuticals May 17, 2019
CAR-T NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer Recruiting National Cancer Institute (NCI) July 13, 2016
CAR-T NCT02772198 T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies Acute Lymphoblastic Leukemia, B-precursor, Non-Hodgkin Lymphoma, B-cell Recruiting Sheba Medical Center May 13, 2016
CAR-T NCT04025216 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma Not yet recruiting Tmunity Therapeutics July 18, 2019
CAR-T NCT02650999 Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas Active, not recruiting Abramson Cancer Center of the University of Pennsylvania January 8, 2016
CAR-T NCT03638167 EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma Recruiting Seattle Children's Hospital August 20, 2018
CAR-T NCT03126864 Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia Active, not recruiting M.D. Anderson Cancer Center April 24, 2017
CAR-T NCT03497819 Autologous CARTmeso/19 Against Pancreatic Cancer Pancreatic Cancer Active, not recruiting First Affiliated Hospital of Wenzhou Medical University April 13, 2018
CAR-T NCT02640209 Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) Active, not recruiting University of Pennsylvania December 28, 2015
CAR-T NCT03502577 BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Recruiting Fred Hutchinson Cancer Research Center April 18, 2018
CAR-T NCT03829540 CD4CAR for CD4+ Leukemia and Lymphoma T-cell Lymphoma, T-cell Leukemia Recruiting Stony Brook University February 4, 2019
CAR-T NCT02919046 Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children Relapsed or Refractory Neuroblastoma Recruiting Sinobioway Cell Therapy Co., Ltd. September 29, 2016
CAR-T NCT03355859 Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma Active, not recruiting Zhao Weili November 28, 2017
CAR-T NCT03344367 Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma Active, not recruiting Peking University November 17, 2017
CAR-T NCT01840566 High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma Non-Hodgkin's Lymphoma Active, not recruiting Memorial Sloan Kettering Cancer Center April 25, 2013
CAR-T NCT02529813 CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia Active, not recruiting M.D. Anderson Cancer Center August 20, 2015
CAR-T NCT03919240 CAR-T Cell Therapy Targeting to CD19 for R/R ALL Acute Lymphoblastic Leukemia With Failed Remission Recruiting The First Affiliated Hospital of Soochow University April 18, 2019
CAR-T NCT03483688 A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects B-cell Non-Hodgkin Lymphoma Not yet recruiting Peking Union Medical College Hospital March 30, 2018
CAR-T NCT02915445 EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent Recruiting Sichuan University September 27, 2016
CAR-T NCT03373097 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma Neuroblastoma, Neuroblastoma Recurrent Recruiting Bambino Gesù Hospital and Research Institute December 14, 2017
CAR-T NCT02664363 EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma Glioblastoma, Gliosarcoma Active, not recruiting Gary Archer Ph.D. January 27, 2016
CAR-T NCT03373071 Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL CD19-ALL, CD19-LNH Recruiting Bambino Gesù Hospital and Research Institute December 14, 2017
CAR-T NCT03344705 Safety and Efficacy Evaluation of IM19 Cells Hematological Malignancies Recruiting Beijing Immunochina Medical Science & Technology Co., Ltd. November 17, 2017
CAR-T NCT03873805 PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, PSCA Positive Recruiting City of Hope Medical Center March 13, 2019
CAR-T NCT03599375 Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia Leukemia, B-Cell Not yet recruiting jiuwei cui July 25, 2018
CAR-T NCT01683279 A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia B Cell Leukemia Active, not recruiting Seattle Children's Hospital September 11, 2012
CAR-T NCT03840317 Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia Acute Lymphocytic Leukemia Recruiting Hebei Senlang Biotechnology Inc., Ltd. February 15, 2019
CAR-T NCT03114670 Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT Adult Acute Myeloid Leukemia Recruiting Affiliated Hospital to Academy of Military Medical Sciences April 14, 2017
CAR-T NCT03240328 The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function HIV/AIDS Recruiting Guangzhou 8th People's Hospital August 7, 2017
CAR-T NCT03262298 Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies Leukemia, Lymphoma Recruiting Affiliated Hospital to Academy of Military Medical Sciences August 25, 2017
CAR-T NCT03275493 Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory Recruiting Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd September 7, 2017
CAR-T NCT02761915 A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART) Relapsed or Refractory Neuroblastoma Recruiting Cancer Research UK May 4, 2016
CAR-T NCT03298828 CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma Acute Lymphoblastic Leukemia, Burkitt Lymphoma Not yet recruiting Third Military Medical University October 2, 2017
CAR-T NCT04020575 Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) Metastatic Breast Cancer Not yet recruiting Minerva Biotechnologies Corporation July 16, 2019
CAR-T NCT03706547 Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM Multiple Myeloma in Relapse, Multiple Myeloma Progression Not yet recruiting Peng Liu October 16, 2018
CAR-T NCT04094766 Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia Recruiting Second Affiliated Hospital of Xi'an Jiaotong University September 19, 2019
CAR-T NCT03593109 Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse Recruiting Second Affiliated Hospital of Xi'an Jiaotong University July 19, 2018
CAR-T NCT03710421 CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, SLAMF7 Positive Recruiting City of Hope Medical Center October 18, 2018
CAR-T NCT03896854 CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia Recruiting Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd April 1, 2019
CAR-T NCT02799550 Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL Leukemia Recruiting The Affiliated Hospital of the Chinese Academy of Military Medical Sciences June 15, 2016
CAR-T NCT03854994 CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Recruiting Yan'an Affiliated Hospital of Kunming Medical University February 26, 2019
CAR-T NCT02706405 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma BCL2 Gene Rearrangement, BCL6 Gene Rearrangement, CD19 Positive, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, MYC Gene Rearrangement, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recruiting Fred Hutchinson Cancer Research Center March 11, 2016
CAR-T NCT02842138 Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma B-cell Lymphoma Active, not recruiting Peking University July 22, 2016
CAR-T NCT03473496 CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma(MM) Recruiting Zhujiang Hospital March 22, 2018
CAR-T NCT02650414 CD22 Redirected Autologous T Cells for ALL B Cell Leukemias, B Cell Lymphomas Recruiting University of Pennsylvania January 8, 2016
CAR-T NCT02431988 Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation Diffuse Large B-Cell Lymphoma Recruiting University College, London May 1, 2015
CAR-T NCT03721068 Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma Neuroblastoma Recruiting UNC Lineberger Comprehensive Cancer Center October 26, 2018
CAR-T NCT02537977 CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy Leukemia, Lymphoma Recruiting Shanghai Tongji Hospital, Tongji University School of Medicine September 2, 2015
CAR-T NCT04067414 Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Primary Mediastinal Large B Cell Lymphoma Recruiting Institute of Hematology & Blood Diseases Hospital August 26, 2019
CAR-T NCT03602157 Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis Recruiting UNC Lineberger Comprehensive Cancer Center July 26, 2018
CAR-T NCT03283631 Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Recurrent Glioblastoma, Recurrent Gliosarcoma Recruiting Gary Archer Ph.D. September 14, 2017
CAR-T NCT03103971 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Adult B Acute Lymphoblastic Leukemia, BCL2 Gene Rearrangement, BCL6 Gene Rearrangement, CD19 Positive, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, MYC Gene Rearrangement, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Adult Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Recruiting Fred Hutchinson Cancer Research Center April 7, 2017
CAR-T NCT03190278 Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia Acute Myeloid Leukemia Recruiting Cellectis S.A. June 16, 2017
CAR-T NCT03473457 CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia(AML) Recruiting Zhujiang Hospital March 22, 2018
CAR-T NCT04083495 CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Peripheral T Cell Lymphoma Not yet recruiting UNC Lineberger Comprehensive Cancer Center September 10, 2019
CAR-T NCT02311621 Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 Neuroblastoma, Ganglioneuroblastoma Recruiting Seattle Children's Hospital December 8, 2014
CAR-T NCT02851589 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Prolymphocytic Leukemia, Diffuse Large Cell Lymphoma Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. August 1, 2016
CAR-T NCT03617198 CD4 CAR+ ZFN-modified T Cells in HIV Therapy Hiv Recruiting University of Pennsylvania August 6, 2018
CAR-T NCT02690545 Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type Recruiting UNC Lineberger Comprehensive Cancer Center February 24, 2016
CAR-T NCT02050347 Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Recruiting Baylor College of Medicine January 30, 2014
CAR-T NCT02672501 A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia Leukemia, B-Cell Recruiting Shanghai GeneChem Co., Ltd. February 3, 2016
CAR-T NCT03081910 Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia Recruiting Baylor College of Medicine March 16, 2017
CAR-T NCT02663297 Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type Recruiting UNC Lineberger Comprehensive Cancer Center January 26, 2016
CAR-T NCT02933775 CD19-redirected Autologous Cells (CAR-CD19 T Cells) CD19 Positive Malignant B-cell Leukemia and Lymphoma Not yet recruiting RenJi Hospital October 14, 2016
CAR-T NCT01953900 iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma Osteosarcoma, Neuroblastoma Recruiting Baylor College of Medicine October 1, 2013
CAR-T NCT03281551 Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Recruiting Pinze Lifetechnology Co. Ltd. September 13, 2017
CAR-T NCT03159819 Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma Advanced Gastric Adenocarcinoma, Pancreatic Adenocarcinoma Recruiting Changhai Hospital May 19, 2017
CAR-T NCT03716856 Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma Refractory or Relapsed Multiple Myeloma Recruiting First Affiliated Hospital of Zhejiang University October 23, 2018
CAR-T NCT03380039 Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma Refractory or Relapsed Multiple Myeloma Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine December 20, 2017
CAR-T NCT01316146 Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Active, not recruiting UNC Lineberger Comprehensive Cancer Center March 16, 2011
CAR-T NCT03685786 CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell Recruiting Shenzhen Second People's Hospital September 26, 2018
CAR-T NCT03642626 MT2017-45: CAR-T Cell Therapy for Heme Malignancies Acute Lymphoblastic Leukemia, Large B-cell Lymphoma Recruiting Masonic Cancer Center, University of Minnesota August 22, 2018
CAR-T NCT02081937 CART-19 Immunotherapy in Mantle Cell Lymphoma Hematopoietic/Lymphoid Cancer, Non-hodgkin Lymphoma,B Cell, Mantle Cell Lymphoma Recruiting Chinese PLA General Hospital March 7, 2014
CAR-T NCT04088890 Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL Recruiting Stanford University September 13, 2019
CAR-T NCT04088864 CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Not yet recruiting Stanford University September 13, 2019
CAR-T NCT03093168 BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma Multiple Myeloma Recruiting The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine March 28, 2017
CAR-T NCT03943472 BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma Multiple Myeloma Not yet recruiting Hrain Biotechnology Co., Ltd. May 9, 2019
CAR-T NCT03598179 XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects Lymphoma, B-Cell, Leukemia, B-cell Active, not recruiting The First Affiliated Hospital with Nanjing Medical University July 25, 2018
CAR-T NCT03070327 BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma Multiple Myeloma Recruiting Memorial Sloan Kettering Cancer Center March 3, 2017
CAR-T NCT03244306 A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma Leukemia Active, not recruiting Seattle Children's Hospital August 9, 2017
CAR-T NCT04007978 Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies B Cell Lymphoma, Acute Lymphoblastic Leukemia Recruiting Wuhan Union Hospital, China July 4, 2019
CAR-T NCT04034446 CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Not yet recruiting Institute of Hematology & Blood Diseases Hospital July 26, 2019
CAR-T NCT03585517 Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) AML Recruiting Beijing Immunochina Medical Science & Technology Co., Ltd. July 13, 2018
CAR-T NCT03915184 Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma Multiple Myeloma Not yet recruiting Carsgen Therapeutics, Ltd. April 15, 2019
CAR-T NCT03692429 alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells Colorectal Cancer Recruiting Celyad (formerly named Cardio3 BioSciences) October 2, 2018
CAR-T NCT03430011 Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma Multiple Myeloma Recruiting Juno Therapeutics, Inc. February 12, 2018
CAR-T NCT01865617 Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma Active, not recruiting Fred Hutchinson Cancer Research Center May 31, 2013
CAR-T NCT02631044 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma Recruiting Juno Therapeutics, Inc. December 15, 2015
CAR-T NCT03720496 Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy Non-hodgkin Lymphoma,B Cell Recruiting Timmune Biotech Inc. October 25, 2018
CAR-T NCT03497533 Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 Non-hodgkin Lymphoma,B Cell Recruiting Timmune Biotech Inc. April 13, 2018
CAR-T NCT03186118 Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia CD 19+ Acute Leukemia Recruiting Seattle Children's Hospital June 14, 2017
CAR-T NCT04011293 A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies Relapsed or Refractory Hematological Malignancies Recruiting Shandong University July 8, 2019
CAR-T NCT02792114 T-Cell Therapy for Advanced Breast Cancer Breast Cancer, Metastatic HER2-negative Breast Recruiting Memorial Sloan Kettering Cancer Center June 7, 2016
CAR-T NCT03056339 Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma Recruiting M.D. Anderson Cancer Center February 17, 2017
CAR-T NCT04077866 B7-H3 CAR-T for Recurrent or Refractory Glioblastoma Recurrent Glioblastoma, Refractory Glioblastoma Not yet recruiting Second Affiliated Hospital, School of Medicine, Zhejiang University September 4, 2019
CAR-T NCT03060356 Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) Malignant Melanoma, Breast Cancer Active, not recruiting University of Pennsylvania February 23, 2017
CAR-T NCT02546739 Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL Leukemia, Lymphoma Not yet recruiting Beijing Doing Biomedical Co., Ltd. September 11, 2015
CAR-T NCT02656147 Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL Leukemia, Lymphoma Not yet recruiting Beijing Doing Biomedical Co., Ltd. January 14, 2016
CAR-T NCT02729493 Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer Liver Neoplasms Recruiting Sinobioway Cell Therapy Co., Ltd. April 6, 2016
CAR-T NCT02725125 Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer Stomach Neoplasms Recruiting Sinobioway Cell Therapy Co., Ltd. March 31, 2016
CAR-T NCT02735291 Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia Leukemia Recruiting Sinobioway Cell Therapy Co., Ltd. April 12, 2016
CAR-T NCT01318317 Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma Active, not recruiting City of Hope Medical Center March 18, 2011
CAR-T NCT02893189 CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation CD19+ Malignancies: Relapse Post-allogeneic Transplant Recruiting University College, London September 8, 2016
CAR-T NCT04026737 Cardiovascular Effects of CART Cell Therapy Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular, Immunotherapy Recruiting Abramson Cancer Center of the University of Pennsylvania July 19, 2019
CAR-T NCT03356795 Intervention of CAR-T Against Cervical Cancer Cervical Cancer Recruiting Shenzhen Geno-Immune Medical Institute November 29, 2017
CAR-T NCT03361748 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) Multiple Myeloma Recruiting Celgene December 5, 2017
CAR-T NCT03768310 CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia Not yet recruiting Baylor College of Medicine December 7, 2018
CAR-T NCT03323944 CAR T Cell Immunotherapy for Pancreatic Cancer Pancreatic Cancer, Cancer of the Pancreas Recruiting University of Pennsylvania October 27, 2017
CAR-T NCT03054298 CAR T Cells in Mesothelin Expressing Cancers Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Mesotheliomas Pleural, Mesothelioma Peritoneum Recruiting University of Pennsylvania February 15, 2017
CAR-T NCT03196830 CAR-T for R/R B-NHL Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30 Recruiting The First Affiliated Hospital of Soochow University June 23, 2017
CAR-T NCT03638193 Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer Pancreatic Cancer Recruiting Shenzhen BinDeBio Ltd. August 20, 2018
CAR-T NCT03207178 Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma Recurrent or Refractory B Cell Malignancy Recruiting Shanghai Longyao Biotechnology Inc., Ltd. July 2, 2017
CAR-T NCT01853631 Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia Recruiting Baylor College of Medicine May 15, 2013
CAR-T NCT03090659 LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma Refractory or Relapsed Multiple Myeloma Enrolling by invitation Nanjing Legend Biotech Co. March 27, 2017
CAR-T NCT03815383 A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma Relapsed or Refractory Multiple Myeloma Recruiting The First Affiliated Hospital with Nanjing Medical University January 24, 2019
CAR-T NCT03751293 A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma Relapsed or Refractory Multiple Myeloma Recruiting Hebei Yanda Ludaopei Hospital November 22, 2018
CAR-T NCT03993743 A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma Recruiting Xijing Hospital June 21, 2019
CAR-T NCT03792633 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL Acute Lymphoid Leukemia Recruiting University of Pennsylvania January 3, 2019
CAR-T NCT04045847 CD147-CART Cells in Patients With Recurrent Malignant Glioma. Recurrent Glioblastoma, CD147 Positive Active, not recruiting Xijing Hospital August 6, 2019
CAR-T NCT03960060 A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer, Bladder Cancer Recruiting Shanghai Sinobioway Sunterra Biotech May 22, 2019
CAR-T NCT03672305 Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC Primary Hepatocellular Carcinoma Not yet recruiting The Second Hospital of Nanjing Medical University September 14, 2018
CAR-T NCT03767725 Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma Multiple Myeloma in Relapse Recruiting Shenzhen Second People's Hospital December 7, 2018
CAR-T NCT03299738 A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Not yet recruiting Cellular Biomedicine Group Ltd. October 3, 2017
CAR-T NCT03752541 Efficacy and Safety Evaluation of BCMA-UCART Multiple Myeloma Recruiting Shanghai Bioray Laboratory Inc. November 26, 2018
CAR-T NCT00881920 Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL Lymphoma, Myeloma, Leukemia Recruiting Baylor College of Medicine April 15, 2009
CAR-T NCT03085173 A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory Recruiting Memorial Sloan Kettering Cancer Center March 21, 2017
CAR-T NCT02744287 Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Prostate Adenocarcinoma Recruiting Bellicum Pharmaceuticals April 20, 2016
CAR-T NCT03229876 Safety and Efficacy Evaluation of CD19-UCART Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) Recruiting Shanghai Bioray Laboratory Inc. July 26, 2017
CAR-T NCT02924753 The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). B-cell Acute Lymphoblastic Leukemia Recruiting Henan Cancer Hospital October 5, 2016
CAR-T NCT03110640 Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Hematopoietic/Lymphoid Cancer, Refractory Chronic Lymphocytic Leukemia Not yet recruiting First Affiliated Hospital of Wenzhou Medical University April 12, 2017
CAR-T NCT02685670 Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma Recruiting The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine February 19, 2016
CAR-T NCT02903810 Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy Hematopoietic/Lymphoid Cancer Recruiting Xuzhou Medical University September 16, 2016
CAR-T NCT02735083 A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19/ALLO-501 Advanced Lymphoid Malignancies Enrolling by invitation Institut de Recherches Internationales Servier April 12, 2016
CAR-T NCT03338972 Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, TNFRSF17 Positive Recruiting Fred Hutchinson Cancer Research Center November 9, 2017
CAR-T NCT02992210 Study on GD2 Positive Solid Tumors by 4SCAR-GD2 Solid Tumor Recruiting Shenzhen Geno-Immune Medical Institute December 14, 2016
CAR-T NCT03366324 Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies Acute Lymphoblastic Leukemia, B Cell Lymphoma Recruiting Wuhan Sian Medical Technology Co., Ltd December 8, 2017
CAR-T NCT03013712 A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer, Gastric Cancer, Hepatic Carcinoma Recruiting First Affiliated Hospital of Chengdu Medical College January 6, 2017
CAR-T NCT03366350 Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies Acute Lymphoblastic Leukemia, B Cell Lymphoma Recruiting Wuhan Sian Medical Technology Co., Ltd December 8, 2017
CAR-T NCT03765177 CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Not yet recruiting Ottawa Hospital Research Institute December 5, 2018
CAR-T NCT03060343 Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer Recruiting Yu Fenglei February 23, 2017
CAR-T NCT03393936 Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma Renal Cell Carcinoma Recruiting Shanghai Sinobioway Sunterra Biotech January 9, 2018
CAR-T NCT03620058 CART22 Alone or in Combination With huCART19 for ALL Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Recruiting University of Pennsylvania August 8, 2018
CAR-T NCT02159495 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia Recruiting City of Hope Medical Center June 10, 2014
CAR-T NCT02746952 Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia B-cell Acute Lymphoblastic Leukemia Recruiting Institut de Recherches Internationales Servier April 21, 2016
CAR-T NCT02315612 Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma Recruiting National Cancer Institute (NCI) December 12, 2014
CAR-T NCT03635632 C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N) Relapsed Neuroblastoma, Refractory Neuroblastoma Recruiting Baylor College of Medicine August 17, 2018
CAR-T NCT03579927 CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma Not yet recruiting M.D. Anderson Cancer Center July 9, 2018
CAR-T NCT03155191 Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia Lymphoblastic Leukemia, Acute Adult Recruiting Takara Bio Inc. May 16, 2017
CAR-T NCT01818323 Phase I Trial: T4 Immunotherapy of Head and Neck Cancer Head and Neck Cancer Recruiting King's College London March 26, 2013
CAR-T NCT02208362 Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Malignant Glioma, Refractory Brain Neoplasm, Recurrent Brain Neoplasm, Glioblastoma Recruiting City of Hope Medical Center August 5, 2014
CAR-T NCT03271515 Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL Leukemia, Lymphoma Not yet recruiting Beijing Doing Biomedical Co., Ltd. September 5, 2017
CAR-T NCT02963038 CAR T Cells for Refractory B Cell Malignancy B-Cell Leukemia, B-Cell Lymphoma Recruiting Hebei Senlang Biotechnology Inc., Ltd. November 15, 2016
CAR-T NCT03573700 Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Recruiting St. Jude Children's Research Hospital June 29, 2018
CAR-T NCT03084380 Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma Not yet recruiting Xinqiao Hospital of Chongqing March 20, 2017
CAR-T NCT02028455 A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia CD19+ Acute Leukemia Recruiting Seattle Children's Hospital January 7, 2014
CAR-T NCT03068416 CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy B-cell Leukemia, B-Cell Lymphoma Recruiting Uppsala University March 1, 2017
CAR-T NCT03064269 CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia B-cell Acute Lymphocytic Leukemia Recruiting Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd February 27, 2017
CAR-T NCT03142646 Safety and Efficacy Evaluation of IM19 CAR-T Cells Leukemia Recruiting Beijing Immunochina Medical Science & Technology Co., Ltd. May 5, 2017
CAR-T NCT03814447 The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer Ovarian Cancer Recruiting Shanghai 6th People's Hospital January 24, 2019
CAR-T NCT03879382 Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES POMES Syndrome, Relapsed and Refractory POMES Syndrome Recruiting Hrain Biotechnology Co., Ltd. March 18, 2019
CAR-T NCT02958384 A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies Myeloid Malignancies Recruiting Southwest Hospital, China November 8, 2016
CAR-T NCT02958397 A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies Myeloid Malignancies Recruiting Southwest Hospital, China November 8, 2016
CAR-T NCT02937103 A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies Leukemia Recruiting Southwest Hospital, China October 18, 2016
CAR-T NCT02710149 A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies Leukemia, Lymphoma Recruiting Southwest Hospital, China March 16, 2016
CAR-T NCT04008394 Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, NK/T-cell Lymphoma, Peripheral T Cell Lymphoma, Hodgkin Lymphoma Recruiting Wuhan Union Hospital, China July 4, 2019
CAR-T NCT02954445 A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies Leukemia, Lymphoma, Multiple Myeloma Recruiting Southwest Hospital, China November 3, 2016
CAR-T NCT02958410 A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies Leukemia, Lymphoma Recruiting Southwest Hospital, China November 8, 2016
CAR-T NCT03559439 CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies B-cell Malignancy, B-cell Lymphoma, B-Cell Acute Lymphoblastic Leukaemia Recruiting Shanghai Tong Ren Hospital June 18, 2018
CAR-T NCT03542799 EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer Metastatic Colorectal Cancer Not yet recruiting Shenzhen Second People's Hospital May 31, 2018
CAR-T NCT03152435 EGFR CART Cells for Patients With Metastatic Colorectal Cancer EGFR-positive Colorectal Cancer Recruiting Shenzhen Second People's Hospital May 15, 2017
CAR-T NCT03994705 Descartes-11 in Multiple Myeloma Multiple Myeloma Not yet recruiting Cartesian Therapeutics June 21, 2019
CAR-T NCT03467256 CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric Recruiting Federal Research Institute of Pediatric Hematology, Oncology and Immunology March 15, 2018
CAR-T NCT02935153 A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies Leukemia, Lymphoma Recruiting Southwest Hospital, China October 17, 2016
CAR-T NCT03146533 CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. B Cell Lymphoma Recruiting Shenzhen Second People's Hospital May 10, 2017
CAR-T NCT02737085 the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) Lymphoma, Large B-Cell, Diffuse Active, not recruiting Southwest Hospital, China April 13, 2016
CAR-T NCT02443831 CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies Acute Lymphoblastic Leukemia, Burkitt Lymphoma Recruiting University College, London May 14, 2015
CAR-T NCT03766126 Lentivirally Redirected CD123 Autologous T Cells in AML Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Refractory Recruiting University of Pennsylvania December 6, 2018
CAR-T NCT03574168 CD19-CAR-T Cells in Patients With R/R B-ALL B-cell Acute Lymphoblastic Leukemia Recruiting Bioceltech Therapeutics, Ltd. June 29, 2018
CAR-T NCT03747965 Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors Solid Tumor, Adult Recruiting Chinese PLA General Hospital November 20, 2018
CAR-T NCT03484702 Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkin Recruiting Celgene April 2, 2018
CAR-T NCT03796390 Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia Acute Myelocytic Leukemia Recruiting Hebei Senlang Biotechnology Inc., Ltd. January 8, 2019
CAR-T NCT03121625 CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies Leukemia, Lymphoma Recruiting Hebei Senlang Biotechnology Inc., Ltd. April 20, 2017
CAR-T NCT03312205 CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis) Recruiting Hebei Senlang Biotechnology Inc., Ltd. October 17, 2017
CAR-T NCT03885076 Gamma Delta T Cells in AML Acute Myeloid Leukemia Recruiting Royal Marsden NHS Foundation Trust March 21, 2019
CAR-T NCT03258047 Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma B Cell Lymphoma Active, not recruiting First Affiliated Hospital of Zhejiang University August 22, 2017
CAR-T NCT03191773 A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma Recruiting Second Affiliated Hospital of Guangzhou Medical University June 19, 2017
CAR-T NCT03960840 CD19-specific CAR-T Cells in CLL/SLL and DLBCL Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma Recruiting Novartis Pharmaceuticals May 23, 2019
CAR-T NCT03907527 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Progressive Disease, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8 Recruiting Fred Hutchinson Cancer Research Center April 9, 2019
CAR-T NCT04028479 The Master Registry of Oncology Outcomes Associated With Testing and Treatment Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma Not yet recruiting Taproot Health July 22, 2019
CAR-T NCT03050190 A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies B-cell Malignancies Recruiting Shenzhen Geno-Immune Medical Institute February 10, 2017
CAR-T NCT04016129 CAR-T Immunotherapy Targeting CD19- ALL B-cell Leukemia Recruiting Shenzhen Geno-Immune Medical Institute July 11, 2019
CAR-T NCT03125577 Combination CAR-T Cell Therapy Targeting Hematological Malignancies B-cell Malignancies Recruiting Shenzhen Geno-Immune Medical Institute April 24, 2017
CAR-T NCT03423706 Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation CD19-chimeric Antigen Receptor T Cells, Relapsed and/or Refractory Acute Lymphoblastic Leukemia, the Haploidentical Hematopoietic Stem Cell Transplantation Recruiting First Affiliated Hospital of Harbin Medical University February 6, 2018
CAR-T NCT04051216 The SMART CART Study: Health Information Technology Leukemia, Acute, Leukemia, Lymphoblastic Enrolling by invitation University of Michigan Rogel Cancer Center August 9, 2019
CAR-T NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Multiple Myeloma Recruiting Celgene July 26, 2018
CAR-T NCT03975907 Clinical Trial to Evaluate BCMA Car-T (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma Multiple Myeloma Not yet recruiting Carsgen Therapeutics, Ltd. June 5, 2019
CAR-T NCT03468153 Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma Lymphoma Recruiting Ruijin Hospital March 16, 2018
CAR-T NCT03330691 A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia Leukemia, Lymphoma Recruiting Seattle Children's Hospital November 6, 2017
CAR-T NCT03684889 CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma Leukemia, Lymphoma Recruiting Seattle Children's Hospital September 26, 2018
CAR-T NCT02721407 Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III/IV Adult Diffuse Large Cell Lymphoma, Stage III/IV Follicular Lymphoma, Stage III/IV Mantle Cell Lymphoma Recruiting Xinqiao Hospital of Chongqing March 29, 2016
CAR-T NCT02786511 Longterm Follow-up of Subjects Treated With bb2121 Multiple Myeloma Enrolling by invitation Celgene June 1, 2016
CAR-T NCT03208556 Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma Relapsed or Refractory B-cell Lymphoma Recruiting Peking University July 5, 2017
CAR-T NCT02652910 Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma Recruiting Xinqiao Hospital of Chongqing January 12, 2016
CAR-T NCT03618381 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma Recruiting Seattle Children's Hospital August 7, 2018
CAR-T NCT02842320 Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) Chronic Myeloid Leukemia Recruiting Centre Hospitalier Universitaire de Besancon July 22, 2016
CAR-T NCT03488160 CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma Lymphoma Recruiting Sinobioway Cell Therapy Co., Ltd. April 4, 2018
CAR-T NCT03492268 Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma Multiple Myeloma Recruiting Shanghai Bioray Laboratory Inc. April 10, 2018
CAR-T NCT03226704 Leukapheresis for CAR-Therapy Manufacturing Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma Recruiting National Cancer Institute (NCI) July 24, 2017
CAR-T NCT03672318 Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma Multiple Myeloma, Immune System Diseases Recruiting UNC Lineberger Comprehensive Cancer Center September 14, 2018
CAR-T NCT03696784 Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases Recruiting UNC Lineberger Comprehensive Cancer Center October 5, 2018
CAR-T NCT03321123 MB-CART19.1 in Patients With R/R ALL Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory Not yet recruiting Shanghai Children's Medical Center October 25, 2017
CAR-T NCT03893019 MB-CART20.1 Melanoma Melanoma (Skin) Recruiting Miltenyi Biotec GmbH March 27, 2019
CAR-T NCT04004637 CD7 CAR-T Cells for Patients With Relapse/Refractory CD7+ NK/T Cell Lymphoma and T-lymphoblastic Lymphoma T-lymphoblastic Lymphoma, NK/T Cell Lymphoma Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. July 2, 2019
CAR-T NCT03389035 Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT Acute Lymphoblastic Leukemia, in Relapse Recruiting Fondazione Matilde Tettamanti Menotti De Marchi Onlus January 3, 2018
CAR-T NCT03664635 MB-CART20.1 Lymphoma Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Recruiting Miltenyi Biotec GmbH September 10, 2018
CAR-T NCT03853616 MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory Recruiting Miltenyi Biotec GmbH February 25, 2019
CAR-T NCT03274219 Study of bb21217 in Multiple Myeloma Multiple Myeloma Recruiting bluebird bio September 6, 2017
CAR-T NCT03117751 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma Recruiting St. Jude Children's Research Hospital April 18, 2017
CAR-T NCT03016377 Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Recruiting UNC Lineberger Comprehensive Cancer Center January 10, 2017
CAR-T NCT03289455 CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia Recruiting Autolus Limited September 21, 2017
CAR-T NCT03287817 CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, DLBCL Recruiting Autolus Limited September 19, 2017
CAR-T NCT03994913 Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma Not yet recruiting Carsgen Therapeutics, Ltd. June 21, 2019
CAR-T NCT03661554 BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma Relapsed and Refractory Multiple Myeloma Recruiting The Pregene (ShenZhen) Biotechnology Company, Ltd. September 7, 2018
CAR-T NCT03690011 Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma Not yet recruiting Baylor College of Medicine October 1, 2018
CAR-T NCT02813252 Long-Term Follow-up Study for Patients Previously Treated With JCAR015 Acute Lymphoblastic Leukemia Active, not recruiting Juno Therapeutics, Inc. June 24, 2016
CAR-T NCT03642496 Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies B-Cell Malignancies Not yet recruiting First Affiliated Hospital Xi'an Jiaotong University August 22, 2018
CAR-T NCT03958656 T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Myeloma-Multiple, Myeloma, Plasma-Cell Recruiting National Cancer Institute (NCI) May 22, 2019
CAR-T NCT03602612 T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Myeloma-Multiple, Myeloma, Plasma-Cell Recruiting National Cancer Institute (NCI) July 27, 2018
CAR-T NCT03288493 P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) Multiple Myeloma Recruiting Poseida Therapeutics, Inc. September 20, 2017
CAR-T NCT03563326 Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART) Neoplasm, Stomach, Metastases, Neoplasm, Neoplasm Seeding Recruiting Jian-Kun Hu June 20, 2018
CAR-T NCT03761056 Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma B-cell Lymphoma Recruiting Kite, A Gilead Company December 3, 2018
CAR-T NCT03624036 Safety and Efficacy of KTE-X19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting Kite, A Gilead Company August 9, 2018
CAR-T NCT02348216 Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL) Recruiting Kite, A Gilead Company January 28, 2015
CAR-T NCT01860937 T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Relapsed B-Cell Acute Lymphoblastic Leukemia Active, not recruiting Memorial Sloan Kettering Cancer Center May 23, 2013
CAR-T/TCR-T NCT02546167 CART-BCMA Cells for Multiple Myeloma Multiple Myeloma Active, not recruiting University of Pennsylvania September 10, 2015
CAR-T NCT02926833 Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Refractory Diffuse Large B Cell Lymphoma Active, not recruiting Kite, A Gilead Company October 6, 2016
CAR-T NCT03704298 Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma Refractory Large B-cell Lymphoma Recruiting Kite, A Gilead Company October 12, 2018
CAR-T NCT03391466 Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting Kite, A Gilead Company January 5, 2018
CAR-T NCT02917083 CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) Hodgkin's Lymphoma, Non-Hodgkin Lymphoma Recruiting Baylor College of Medicine September 28, 2016
CAR-T NCT03271632 Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma Multiple Myeloma Recruiting Shenzhen Geno-Immune Medical Institute September 5, 2017
CAR-T NCT03310619 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Recruiting Celgene October 16, 2017
CAR-T NCT03389230 Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Glioblastoma, HER2/Neu Positive, Malignant Glioma, Recurrent Glioma, Refractory Glioma, WHO Grade III Glioma Recruiting City of Hope Medical Center January 3, 2018
CAR-T NCT04002401 Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) Refractory Large B-cell Lymphoma Not yet recruiting Gilead Sciences June 28, 2019
CAR-T NCT03331198 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic Recruiting Juno Therapeutics, Inc. November 6, 2017
CAR-T NCT03483103 Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse Recruiting Juno Therapeutics, Inc. March 30, 2018
CAR-T NCT03744676 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND - OUTREACH) Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Neoplasms by Histologic Type, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Disorder Recruiting Juno Therapeutics, Inc. November 16, 2018
CAR-T NCT03568461 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma Follicular Lymphoma Recruiting Novartis Pharmaceuticals June 25, 2018
CAR-T NCT02445248 Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients Diffuse Large B-cell Lymphoma (DLBCL) Active, not recruiting Novartis Pharmaceuticals May 15, 2015
CAR-T NCT03181126 A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Recruiting AbbVie June 8, 2017
CAR-T NCT03651128 Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Multiple Myeloma Recruiting Celgene August 29, 2018
TCR-T NCT03925896 Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients Nasopharyngeal Carcinoma Recruiting Sun Yat-sen University April 24, 2019
TCR-T NCT03778814 TCR-T Cell for Immunotherapy of Lung Cancer and Other Solid Tumors Nonsmall Cell Lung Cancer, Solid Tumor, Adult Recruiting Second Affiliated Hospital of Guangzhou Medical University December 18, 2018
TCR-T NCT03891706 Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors Lung Cancer, Melanoma Recruiting Guangzhou FineImmune Biotechnology Co., LTD. March 27, 2019
TCR-T NCT04044950 A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer Papillomavirus Infections, Oropharyngeal Neoplasms Not yet recruiting National Cancer Institute (NCI) August 5, 2019
TCR-T NCT03578406 HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer Cervical Cancer, Head and Neck Squamous Cell Carcinoma Recruiting Xinqiao Hospital of Chongqing July 6, 2018
TCR-T NCT03648697 EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC Nasopharyngeal Carcinoma Not yet recruiting Fujian Cancer Hospital August 27, 2018
TCR-T NCT04015336 E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer Papillomavirus Infections, Oropharyngeal Neoplasms Recruiting National Cancer Institute (NCI) July 11, 2019
TCR-T NCT03326921 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant HLA-A*0201 HA-1 Positive Cells Present, Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Donor, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Blast Cells Present, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Minimal Residual Disease, Mixed Phenotype Acute Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Recruiting Fred Hutchinson Cancer Research Center October 31, 2017
TCR-T NCT02719782 A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation Recurrent Hepatocellular Carcinoma Recruiting Lion TCR Pte. Ltd. March 25, 2016
TCR-T NCT03937791 Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL Recruiting National Cancer Institute (NCI) May 6, 2019
TCR-T NCT02858310 E7 TCR T Cells for Human Papillomavirus-Associated Cancers Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases Recruiting National Cancer Institute (NCI) August 8, 2016
TCR-T NCT03029273 NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC Lung Cancer, Nonsmall Cell, Recurrent Recruiting Guangzhou Institute of Respiratory Disease January 24, 2017
TCR-T NCT03970382 A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Solid Tumor Recruiting PACT Pharma, Inc. May 31, 2019
TCR-T NCT03747484 Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Other Skin Recruiting Fred Hutchinson Cancer Research Center November 20, 2018
TCR-T NCT03392545 Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1) High Grade Glioma, Glioblastoma, Glioma of Brainstem, Glioma, Malignant Recruiting Beijing Tiantan Hospital January 8, 2018
TCR-T NCT03691376 NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer HLA-A*0201 Positive Cells Present, HLA-DP4 Positive Cells Present, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma Recruiting Roswell Park Cancer Institute October 1, 2018
TCR-T NCT02686372 TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation Hepatocellular Carcinoma Recruiting Lion TCR Pte. Ltd. February 19, 2016
TCR-T NCT03462316 NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma Bone Sarcoma, Soft Tissue Sarcoma Recruiting Sun Yat-sen University March 12, 2018
TCR-T NCT03899415 TCR-Redirected T Cells Therapy in Patient With HBV Related HCC Hepatocellular Carcinoma Recruiting Beijing 302 Hospital April 2, 2019
TCR-T NCT03912831 Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer Recruiting Kite, A Gilead Company April 11, 2019
TCR-T NCT03391791 Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors Solid and Hematological Malignancies Enrolling by invitation Adaptimmune January 5, 2018
TCR-T NCT03301168 Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic Active, not recruiting Bellicum Pharmaceuticals October 4, 2017
TCR-T NCT02654821 Study With T-cel Receptor Gene Therapy in Metastatic Melanoma Stage IV Skin Melanoma, Eye; Melanoma Active, not recruiting The Netherlands Cancer Institute January 13, 2016
TCR-T NCT03717480 Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies Hematologic Malignancy Recruiting Dana-Farber Cancer Institute October 24, 2018
TCR-T NCT02457650 T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Cancer, Synovial Sarcoma, Other Metastatic Solid Cancers Recruiting Shenzhen Second People's Hospital May 29, 2015
TCR-T NCT03939585 Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoproliferative Disorders Not yet recruiting Case Comprehensive Cancer Center May 7, 2019
TCR-T NCT03971747 AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma Hepatocellular Carcinoma Not yet recruiting Cellular Biomedicine Group Ltd. June 3, 2019
TCR-T NCT02065869 Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome, Primary Immunodeficiency, Anemia, Aplastic, Osteopetrosis, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell Active, not recruiting Bellicum Pharmaceuticals February 19, 2014
TCR-T NCT03907852 Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic Recruiting TCR2 Therapeutics April 9, 2019
TCR-T NCT03503968 TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms Safety, Tolerability, Feasibility, Treatment Efficacy Recruiting Medigene AG April 20, 2018
TCR-T NCT02650986 Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1 Adult Solid Neoplasm Recruiting Roswell Park Cancer Institute January 8, 2016
TCR-T NCT03399448 NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma Recruiting University of Pennsylvania January 16, 2018
TCR-T NCT03297697 Minimal Residual Disease in Peripheral T-cell Lymphoma Peripheral T Cell Lymphoma Recruiting Washington University School of Medicine September 29, 2017
TCR-T NCT03354390 HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma Kidney Cancer Recruiting National Heart, Lung, and Blood Institute (NHLBI) November 28, 2017
TCR-T NCT03996018 T-cell Responses to Concurrent HIV and Herpesvirus Infections HIV, HIV Infections Recruiting St. Jude Children's Research Hospital June 24, 2019
TCR-T NCT03686124 TCR-engineered T Cells in Solid Tumors Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer Recruiting Immatics US, Inc. September 26, 2018
TCR-T NCT03422224 ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation Renal Transplant Rejection, Immune Repertoire, Transplant; Complication, Rejection, Alloreactivity Recruiting Medical University of Vienna February 5, 2018
TCR-T NCT02870244 Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes Melanoma Recruiting Loyola University August 17, 2016
TCR-T NCT02869217 Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma, Melanoma, Esophageal Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Liver Cancer Recruiting University Health Network, Toronto August 16, 2016
TCR-T NCT03159585 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors Liver Cancer Stage IV, Gastric Cancer Stage IV, Esophageal Cancer, Stage IV, Bone and Soft Tissue Tumors, Breast Cancer Stage IV, Bladder Carcinoma Stage IV, Prostate Carcinoma Stage IV, Thyroid Cancer Stage IV, Ovarian Cancer Stage IV, Solid Tumor Recruiting Zhujiang Hospital May 18, 2017
TCR-T NCT03236558 The Role of the Thymus in Type I Diabetes. Type1 Diabetes Not yet recruiting University Hospital, Toulouse August 2, 2017
TCR-T NCT03247309 TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) Solid Tumor, Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer Recruiting Immatics US, Inc. August 11, 2017
TCR-T NCT03047746 Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF Acquired Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Inherited Bone Marrow Failure Syndromes Recruiting Children's Hospital of Philadelphia February 9, 2017
TCR-T NCT03579875 T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes Recruiting Masonic Cancer Center, University of Minnesota July 9, 2018
TCR-T NCT03412877 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Glioblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancer Recruiting National Cancer Institute (NCI) January 29, 2018
TCR-T NCT02366546 Investigator Initiated Phase 1 Study of TBI-1301 Solid Tumors Active, not recruiting Mie University February 19, 2015
TCR-T NCT02096614 Investigator Initiated Phase 1 Study of TBI-1201 Solid Tumors Recruiting Mie University March 26, 2014
TCR-T NCT03709706 Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab Neoplasms Recruiting GlaxoSmithKline October 17, 2018
TCR-T NCT03649529 Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy Malignant Melanoma Recruiting Timmune Biotech Inc. August 28, 2018
TCR-T NCT03017131 Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Recruiting Roswell Park Cancer Institute January 11, 2017
TCR-T NCT02588612 NY-ESO-1ᶜ²⁵⁹T for Advanced NSCLC Neoplasms Active, not recruiting GlaxoSmithKline October 28, 2015
TCR-T NCT03132792 AFPᶜ³³²T in Advanced HCC Hepatocellular Cancer Recruiting Adaptimmune April 28, 2017
TCR-T NCT02743611 Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma Active, not recruiting Bellicum Pharmaceuticals April 19, 2016
TCR-T NCT03441100 TCR-engineered T Cells in Solid Tumors Including NSCLC and HCC Patients Solid Tumor, Adult, Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Nonsmall Cell Lung Cancer, Liver Cancer, Lung Cancer Recruiting Immatics US, Inc. February 21, 2018
TCR-T NCT03615144 TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors Non-Malignant Hematologic Disorders Recruiting Memorial Sloan Kettering Cancer Center August 3, 2018
TCR-T NCT02770820 Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia Acute Myeloid Leukemia, EBV-Positive Neoplastic Cells Present, HLA-A*0201 Positive Cells Present, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Elevated WT1 Active, not recruiting Fred Hutchinson Cancer Research Center May 12, 2016
TCR-T NCT03139370 Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers Solid Tumor Recruiting Kite, A Gilead Company May 3, 2017
TCR-T NCT03745326 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer Recruiting National Cancer Institute (NCI) November 19, 2018
TCR-T NCT03190941 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer Recruiting National Cancer Institute (NCI) June 19, 2017
TCR-T NCT02408016 Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, WT1 Positive Active, not recruiting Fred Hutchinson Cancer Research Center April 3, 2015
TCR-T NCT03250325 Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma Synovial Sarcoma Active, not recruiting Takara Bio Inc. August 15, 2017
TCR-T NCT03953599 CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients B Cell Malignancy Not yet recruiting Hebei Yanda Ludaopei Hospital May 16, 2019
TCR-T NCT01586403 Transfer of Genetically Engineered Lymphocytes in Melanoma Patients Melanoma Active, not recruiting Loyola University April 26, 2012
TCR-T NCT00001350 Study of Autoimmune Lymphoproliferative Syndrome (ALPS) Autoimmune Lymphproliferative Syndrome Recruiting National Institute of Allergy and Infectious Diseases (NIAID) November 4, 1999
TCR-T NCT03240861 Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm Recruiting Jonsson Comprehensive Cancer Center August 7, 2017
TCR-T NCT01640301 Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Donor, Hematopoietic Cell Transplant Recipient, HLA-A*0201 Positive Cells Present, Recurrent Acute Myeloid Leukemia Active, not recruiting Fred Hutchinson Cancer Research Center July 13, 2012
TCR-T NCT01967823 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer Recruiting National Cancer Institute (NCI) October 23, 2013
TCR-T NCT02111850 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer Recruiting National Cancer Institute (NCI) April 11, 2014
TCR-T NCT03093688 Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma, Gastric Cancer, Renal Cell Carcinoma Recruiting Shanghai Public Health Clinical Center March 28, 2017
TCR-T NCT02652468 TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma Lymphoma Active, not recruiting University of Wisconsin, Madison January 11, 2016
TCR-T NCT03391778 Long Term Follow-Up of Subjects Exposed to GSK3377794 Neoplasms Recruiting GlaxoSmithKline January 5, 2018
TCR-T NCT03733249 Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immunodeficiency, Anemia, Aplastic, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell Enrolling by invitation Bellicum Pharmaceuticals November 7, 2018
TCR-T NCT02840110 Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression Enrolling by invitation Unum Therapeutics Inc. July 21, 2016
TCR-T NCT03849651 TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML) Recruiting St. Jude Children's Research Hospital February 21, 2019
TCR-T NCT02646839 KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes Enrolling by invitation Michael Pulsipher, MD January 6, 2016
TCR-T NCT02942173 CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Leukemia, Lymphoma, Myelodysplastic Syndromes, GvHD, Opportunistic Infections, Graft-versus-Host Disease Recruiting Federal Research Institute of Pediatric Hematology, Oncology and Immunology October 21, 2016
TCR-T NCT00622232 A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial HIV Infections Active, not recruiting VIRxSYS Corporation February 22, 2008
TCR-T NCT01982890 Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over Time Telomere Length in Healthy Controls Enrolling by invitation Université de Sherbrooke November 13, 2013
TCR-T NCT03132922 MAGE-A4ᶜ¹º³²T for Multi-Tumor Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma Recruiting Adaptimmune April 28, 2017
TCR-T NCT03603002 Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer Non-small Cell Lung Cancer Stage I Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 27, 2018
TCR-T NCT03168438 NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma Neoplasms Recruiting GlaxoSmithKline May 30, 2017
TCR-T NCT03921047 Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant Acute Myeloid Leukemia Recruiting University of Southern California April 19, 2019
TCR-T NCT02636855 Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Solid and Hematological Malignancies Recruiting Adaptimmune December 22, 2015
TCR-T NCT02776813 Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Lymphoma Active, not recruiting Unum Therapeutics Inc. May 18, 2016
TCR-T NCT03369353 Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) Graft Vs Host Disease, Inflammatory Bowel Diseases, Functional Gastrointestinal Disorders Enrolling by invitation Boston Children’s Hospital December 12, 2017
TCR-T NCT03265106 A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood Recruiting Shenzhen BinDeBio Ltd. August 29, 2017
TCR-T NCT03880279 Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma Lymphoma, B-Cell Not yet recruiting Triumvira Immunologics, Inc. March 19, 2019
TCR-T NCT02774291 Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain Recruiting Albert Einstein College of Medicine May 17, 2016
TCR-T NCT03587285 A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer Prostatic Neoplasms Active, not recruiting Guangzhou University of Traditional Chinese Medicine July 16, 2018
TCR-T NCT02133196 T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas Recruiting National Cancer Institute (NCI) May 7, 2014
TCR-T NCT03680560 Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers Solid Tumor, HER-2 Protein Overexpression Recruiting Unum Therapeutics Inc. September 21, 2018
TCR-T NCT03738228 Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Positive Lymph Node, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8 Recruiting National Cancer Institute (NCI) November 12, 2018
TCR-T NCT00910650 Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Metastatic Melanoma Active, not recruiting Jonsson Comprehensive Cancer Center June 1, 2009
TCR-T NCT03156101 A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Lymphoma Recruiting Shenzhen BinDeBio Ltd. May 17, 2017
TCR-T NCT03118687 Human Immunome Program Healthy Enrolling by invitation Vanderbilt University Medical Center April 18, 2017
TCR-T NCT01744223 Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma Active, not recruiting Bellicum Pharmaceuticals December 6, 2012
TCR-T NCT03515551 Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers Select Advanced Solid Tumors Recruiting Immunocore Ltd May 3, 2018
TCR-T NCT01827579 Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT) Haematological Malignancies Active, not recruiting University College, London April 9, 2013
TCR-T NCT03619551 Conditioning SCID Infants Diagnosed Early SCID Recruiting Michael Pulsipher, MD August 8, 2018
TCR-T NCT02737046 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Adult T-cell Leukemia-Lymphoma, ATLL Recruiting University of Miami April 13, 2016
TCR-T NCT01884168 Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy Malignant Tumor Recruiting Capital Medical University June 21, 2013
TCR-T NCT03634683 A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation Recurrent Hepatocellular Carcinoma Not yet recruiting Lion TCR Pte. Ltd. August 16, 2018
TCR-T NCT03318900 T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma Recruiting M.D. Anderson Cancer Center October 24, 2017
TCR-T NCT03559803 A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer Cervical Cancer Active, not recruiting Sichuan University June 18, 2018
TCR-T NCT01697527 Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies Malignant Neoplasm Active, not recruiting Jonsson Comprehensive Cancer Center October 2, 2012
TCR-T NCT02210741 Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease Graves Disease Not yet recruiting National Taiwan University Hospital August 7, 2014
TCR-T NCT02761122 Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen) Lichen Planus Active, not recruiting Institut Pasteur May 4, 2016
TCR-T NCT03879876 Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients Pediatric Patients, Any Type of Severe Combined Immunodeficiency (SCID), Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Not yet recruiting Assistance Publique - Hôpitaux de Paris March 19, 2019
TCR-T NCT03340155 Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases Psoriasis, Cutaneous T Cell Lymphoma, Lymphoproliferative Disorders, Eczema, Lichen Planus, Prurigo, Pruritus, Polymorphic Light Eruption, Graft Vs Host Disease, Mastocytosis, Vitiligo Recruiting Medical University of Graz November 13, 2017
TCR-T NCT02590328 Neonatal Screening of Severe Combined Immunodeficiencies Severe Combined Immunodeficiency, Neonatal Screening Recruiting Children's Hospital of Fudan University October 29, 2015
TCR-T NCT03551795 Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor Malignant Solid Tumor Recruiting Xiaoyan Zhang June 11, 2018
TCR-T NCT02102893 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan This Study Plans to Include 600 GEP-NET Patients. Enrolling by invitation National Health Research Institutes, Taiwan April 3, 2014
TCR-T NCT01906632 Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy Malignant Tumor Recruiting Capital Medical University July 24, 2013
TCR-T NCT01050296 Molecular Analysis Of Solid Tumors Pediatric Solid Tumors Recruiting St. Jude Children's Research Hospital January 15, 2010
TCR-T NCT03967223 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors Neoplasms Not yet recruiting GlaxoSmithKline May 30, 2019
TCR-T NCT03407170 Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Advanced Melanoma Active, not recruiting Merck Sharp & Dohme Corp. January 23, 2018
TCR-T NCT03523429 PETHEMA-BLIN-01/PET069014 (BLIN-01) Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL Recruiting PETHEMA Foundation May 14, 2018
TCR-T NCT03129061 Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Squamous Cell Carcinoma of the Head and Neck Recruiting CellSight Technologies, Inc. April 26, 2017
TCR-T NCT03601286 Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency Severe Combined Immunodeficiency, X-Linked Recruiting Great Ormond Street Hospital for Children NHS Foundation Trust July 26, 2018
TCR-T NCT01343043 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Neoplasms Active, not recruiting GlaxoSmithKline April 27, 2011
TCR-T NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms Recruiting Merck Sharp & Dohme Corp. May 14, 2019
TCR-T NCT02992743 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Neoplasms Recruiting GlaxoSmithKline December 14, 2016
TCR-T NCT03852823 Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors SG001, PD-1, Advanced Solid Tumors Not yet recruiting CSPC ZhongQi Pharmaceutical Technology Co., Ltd. February 25, 2019
TCR-T NCT02989064 MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma Recruiting Adaptimmune December 12, 2016
TCR-T NCT03397355 Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy. Lung Cancer Recruiting China-Japan Friendship Hospital January 12, 2018
TCR-T NCT02592577 MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Non-Small Cell Lung Cancer, Carcinoma Recruiting Adaptimmune October 30, 2015
CAR-T/TCR-T NCT02706392 Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Triple-Negative Breast Carcinoma Recruiting Fred Hutchinson Cancer Research Center March 11, 2016
CAR-T/TCR-T NCT03545815 Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. Solid Tumor, Adult Recruiting Chinese PLA General Hospital June 4, 2018
CAR-T/TCR-T NCT00085930 Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients Neuroblastoma Active, not recruiting Baylor College of Medicine June 21, 2004
CAR-T/TCR-T NCT00924326 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell Active, not recruiting National Cancer Institute (NCI) June 18, 2009
CAR-T/TCR-T NCT03904069 Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Relapsed/Refractory Acute Myeloid Leukemia Not yet recruiting Amgen April 4, 2019
CAR-T/TCR-T NCT01430390 In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies Acute Lymphocytic Leukemia, Lymphoma Recruiting Memorial Sloan Kettering Cancer Center September 8, 2011
CAR-T/TCR-T NCT03166878 A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma B Cell Leukemia, B Cell Lymphoma Recruiting Chinese PLA General Hospital May 25, 2017
CAR-T/TCR-T NCT03980691 Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir HIV/AIDS Recruiting Guangzhou 8th People's Hospital June 10, 2019
CAR-T/TCR-T NCT02624258 Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma Hodgkin Lymphoma Active, not recruiting University of Pennsylvania December 8, 2015
CAR-T/TCR-T NCT02030834 Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas Active, not recruiting University of Pennsylvania January 9, 2014
CAR-T/TCR-T NCT03740256 Binary Oncolytic Adenovirus in Combination With HER2-Specific CAR VST, Advanced HER2 Positive Solid Tumors (VISTA) Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma Not yet recruiting Baylor College of Medicine November 14, 2018
CAR-T/TCR-T NCT03941626 Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer Recruiting Shenzhen BinDeBio Ltd. May 8, 2019
CAR-T/TCR-T NCT03638206 Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma Recruiting Shenzhen BinDeBio Ltd. August 20, 2018
CAR-T/TCR-T NCT01192464 EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Active, not recruiting Baylor College of Medicine September 1, 2010
CAR-NK NCT03692767 Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma Refractory B-Cell Lymphoma Not yet recruiting Allife Medical Science and Technology Co., Ltd. October 2, 2018
CAR-NK NCT03690310 Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma Refractory B-Cell Lymphoma Not yet recruiting Allife Medical Science and Technology Co., Ltd. October 1, 2018
CAR-NK NCT03692663 Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer Castration-resistant Prostate Cancer Not yet recruiting Allife Medical Science and Technology Co., Ltd. October 2, 2018
CAR-NK NCT03692637 Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer Epithelial Ovarian Cancer Not yet recruiting Allife Medical Science and Technology Co., Ltd. October 2, 2018
CAR-NK NCT03415100 Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours Solid Tumours Recruiting The Third Affiliated Hospital of Guangzhou Medical University January 30, 2018
CAR-NK NCT03940820 Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors Solid Tumor Recruiting Asclepius Technology Company Group (Suzhou) Co., Ltd. May 7, 2019
CAR-NK NCT03940833 Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM Multiple Myeloma Recruiting Asclepius Technology Company Group (Suzhou) Co., Ltd. May 7, 2019
CAR-NK NCT03824964 Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma Refractory B-Cell Lymphoma Not yet recruiting Allife Medical Science and Technology Co., Ltd. January 31, 2019
CAR-NK NCT03941457 Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer Pancreatic Cancer Recruiting Asclepius Technology Company Group (Suzhou) Co., Ltd. May 8, 2019
CAR-NK NCT03931720 Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor Malignant Tumor Recruiting Asclepius Technology Company Group (Suzhou) Co., Ltd. April 30, 2019
CAR-NK NCT03579927 CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma Not yet recruiting M.D. Anderson Cancer Center July 9, 2018
CAR-NK NCT03056339 Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma Recruiting M.D. Anderson Cancer Center February 17, 2017
CAR-NK NCT03383978 Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma Glioblastoma Recruiting Johann Wolfgang Goethe University Hospital December 27, 2017
CAR-NK NCT04033302 Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma Recruiting Shenzhen Geno-Immune Medical Institute July 26, 2019
CAR-NK NCT03049449 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Lymphoma, Large-Cell, Anaplasitc, Hodgkin Disease, Lymphoma, Hodgkins, Enteropathy-Associated T-Cell Lymphoma Active, not recruiting National Cancer Institute (NCI) February 10, 2017
CAR-NK NCT04008394 Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, NK/T-cell Lymphoma, Peripheral T Cell Lymphoma, Hodgkin Lymphoma Recruiting Wuhan Union Hospital, China July 4, 2019
CAR-NKT NCT03882840 Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I Anti-cancer Cell Immunotherapy, T Cell and NK Cell Recruiting Second Affiliated Hospital of Guangzhou Medical University March 20, 2019
CAR-NKT NCT03294954 GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma Neuroblastoma Recruiting Baylor College of Medicine September 27, 2017
CAR-NKT NCT03774654 CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma Not yet recruiting Baylor College of Medicine December 13, 2018
CAR-Macrophage NCT03608618 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma Recruiting MaxCyte, Inc. August 1, 2018

Immune Cell Vaccine

Immune Cell-based TherapiesVaccine usually refers to biological products made from pathogenic microorganisms providing active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. With the deeper understanding of the immune system and advances in biotechnology, scientists discovered a novel form of vaccines - cell vaccines, which are referred to dead or living cells that are used to induce an immune response in the recipient, with the aim of protecting them from future disease or infection. Compared to non-immune cells, immune cells are better choice in the production of cell vaccines for their significant roles in the adaptive immune responses. T-cell vaccination is immunization with inactivated autoreactive T cells (T cell vaccine, TCV). The concept of T-cell vaccination is, at least partially, analogous to classical vaccination against infectious disease. However, the agents to be eliminated or neutralized are not foreign microbial agents but a pathogenic autoreactive T-cell population. Research on T-cell vaccination so far has focused mostly on multiple sclerosis and to a lesser extent on rheumatoid arthritis, Crohn's disease and AIDS. Another immune cells that are widely studied for vaccination are dendritic cells (DCs). DC vaccine has been introduced as a new therapeutic strategy in cancer patients. DC-based immunotherapy is safe and can promote antitumor immune responses and prolong survival of cancer patients. DC-based immunotherapy approach can be employed in a couple of ways: direct targeting/stimulating of the DCs in vivo to accentuate their anti-cancer phenotype; stimulation of the DCs ex vivo and infusing them back into the host for carrying out anti-cancer effector function. Sipuleucel-T is the first DCs- based cancer vaccine, approved by the US Food and Drug Administration (FDA) for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC).

References

  1. Virella, G. (2019). Medical Immunology (6th ed.). Boca Raton, Florida: CRC Press.
  2. Tyagi, R. (2019). Immune Response Activation and Immunomodulation. London: IntechOpen.
  3. Smith, W. M., Purvis, I. J., Bomstad, C. N., Labak, C. M., Velpula, K. K., Tsung, A. J., ... & Asuthkar, S. (2019). Therapeutic targeting of immune checkpoints with small molecule inhibitors. American journal of translational research, 11(2), 529.
  4. Scott, A. M., Allison, J. P., & Wolchok, J. D. (2012). Monoclonal antibodies in cancer therapy. Cancer Immunity Archive, 12(1), 14.
  5. Lee, S., & Ballow, M. (2010). Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. Journal of Allergy and Clinical Immunology, 125(4), 814-820.
  6. Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62-68.
  7. Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017). Engineering natural killer cells for cancer immunotherapy. Molecular Therapy, 25(8), 1769-1781.
  8. Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016). Driving CAR T-cells forward. Nature reviews Clinical oncology, 13(6), 370.
  9. Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019). Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Frontiers in Immunology, 10, 1205.
  10. Hellings, N., Raus, J., & Stinissen, P. (2004). T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmunity Reviews, 3(4), 267-275.
  11. Santos, P. M., & Butterfield, L. H. (2018). Dendritic cell–based cancer vaccines. The Journal of Immunology, 200(2), 443-449.

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive the latest news and insights to your inbox.